(Q36816030)

16 August 2017

1 reference

title

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response (English)

1 reference

16 August 2017

1 reference

1 reference

Enriqueta Felip

1

0 references

Rafael Rosell

series ordinal

2

object named as

Rafael Rosell

1 reference

16 August 2017

language of work or name

1 reference

1 May 2007

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

261-268

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

ERCC1 and clinical resistance to platinum-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Nucleotide excision repair in E. coli and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Aging and genome maintenance: lessons from the mouse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

MZF1 possesses a repressively regulatory function in ERCC1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

DNA repair by ERCC1 in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.3.261

21 January 2018

Identifiers

DOI

10.1586/14737159.7.3.261

1 reference

16 August 2017

1 reference